AlphaQuest LLC Decreases Stake in USANA Health Sciences, Inc. (NYSE:USNA)

AlphaQuest LLC lowered its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 87.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 851 shares of the company’s stock after selling 5,752 shares during the quarter. AlphaQuest LLC’s holdings in USANA Health Sciences were worth $31,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the company. Amundi grew its holdings in shares of USANA Health Sciences by 85.3% during the 4th quarter. Amundi now owns 4,872 shares of the company’s stock worth $170,000 after purchasing an additional 2,243 shares during the period. Principal Financial Group Inc. lifted its position in USANA Health Sciences by 2.8% during the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company’s stock worth $1,924,000 after acquiring an additional 1,480 shares in the last quarter. Rhumbline Advisers lifted its position in USANA Health Sciences by 39.8% during the 4th quarter. Rhumbline Advisers now owns 49,390 shares of the company’s stock worth $1,773,000 after acquiring an additional 14,068 shares in the last quarter. R Squared Ltd acquired a new position in USANA Health Sciences during the 4th quarter worth approximately $28,000. Finally, Pacer Advisors Inc. lifted its position in USANA Health Sciences by 8.8% during the 4th quarter. Pacer Advisors Inc. now owns 592,001 shares of the company’s stock worth $21,247,000 after acquiring an additional 47,745 shares in the last quarter. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Insider Buying and Selling at USANA Health Sciences

In other news, CEO Jim Brown sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total value of $147,350.00. Following the completion of the sale, the chief executive officer now directly owns 15,716 shares in the company, valued at approximately $463,150.52. The trade was a 24.14 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joshua Foukas sold 5,732 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total value of $186,519.28. The disclosure for this sale can be found here. Insiders have sold a total of 15,920 shares of company stock valued at $500,285 in the last three months. Corporate insiders own 0.33% of the company’s stock.

USANA Health Sciences Stock Down 0.2 %

Shares of USNA opened at $27.27 on Friday. The business’s 50 day moving average is $31.81 and its two-hundred day moving average is $35.47. USANA Health Sciences, Inc. has a 52-week low of $26.78 and a 52-week high of $49.78. The firm has a market cap of $515.44 million, a price-to-earnings ratio of 9.63, a PEG ratio of 0.93 and a beta of 0.98.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. On average, equities analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

USNA has been the topic of several recent research reports. StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. DA Davidson reduced their price target on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, February 27th. Finally, Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.